SCTV 01C
Alternative Names: Bivalent recombinant trimeric S-protein vaccine - Sinocelltech; SCTV-01CLatest Information Update: 23 Feb 2024
Price :
$50 *
At a glance
- Originator Sinocelltech
- Class COVID-19 vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 09 Feb 2024 Sinocelltech withdraws a phase-II trial for COVID-2019 infections (Prevention, In volunteers) (IM, Injection), prior to enrolment as there was not a need of this trial any more (NCT05308602)
- 04 Aug 2023 Sinocelltech completes a phase I/II trial in COVID-2019 infections (Prevention) in China (IM) (NCT05148091)
- 13 Apr 2022 Sinocelltech plans a phase-II trial for COVID-2019 infections (Prevention, In volunteers, In children, In adults, In the elderly) in April 2022 (IM, Injection) (NCT05308602)